N/A N=44 Calibration and Validation of Masimo's O3 Regional Oximetry Device in Neonates, Infants and Children
Surgery
Primary: Accuracy of Sensor by Arms Calculation of Percent rSO2 — 5.0 %rSO2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=418 A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
Chronic Kidney Disease (CKD)
Primary: Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL) — 61.9330; 63.3305 Percentage of Weeks
Phase 3 N=772 A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
Plaque Psoriasis
Primary: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) — 62.3; 63.8; 5.8 Percentage of Participants — p=<0.001
Phase 2 N=46 EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
Venous Thromboembolism
Primary: Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events — 0; 0; 0; 0 Participants
N/A N=29 Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients
Heart Failures
Primary: The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI) — 26.3; 36.1; 32.3; 44.6 events per hour
Phase 3 N=1,164 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · Connective Tissue Disease · Autoimmune Disease
Primary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 31.8; 35.2; 29.3 percentage of participants
Phase 2 N=175 Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Leukemia · Acute Myeloid Leukemia · AML
Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants
Phase 4 N=8 A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) — 5496; 832 nanogram per milliliter (ng/mL)
N/A N=25 Foot Neuromodulation for Nocturnal Enuresis
Bedwetting
Primary: Decrease in Nocturnal Enuresis — 16 Participants
Phase 2 N=15 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Thrombosis
Primary: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28
Phase 2 N=102 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…
Phase 2 N=30 A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
Adenocarcinoma of the Prostate
Primary: Number of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Positive Clusters — 0.251560; 0.269518 VEGFR1+ clusters per hpf — p=0.345
Phase 2 N=64 A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Primary: Change of HbA1c Level From Baseline — -0.21; -0.17; -0.43; -0.04 (%)
Phase 2 N=172 A Study in Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Phase 4 N=62 MI Varnish for the Prevention of White Spot Lesions
White Spot Lesion · Orthodontic Treatment
Primary: Enamel Decalcification Index (EDI) Scores — 1.038; 1; 1.308; 2.724 scores on a scale